Silver Book Fact

Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.

Early Treatment Diabetic Retinopathy Study. http://www.nei.nih.gov/neitrials/static/study53.asp

Reference

Title
Early Treatment Diabetic Retinopathy Study
Authors
National Institutes of Health, National Eye Institute
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • In general, every 10 mmHg reduction in systolic blood pressure reduces the risk of diabetes complications by 12%.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of over $472.1 million– in 1994 dollars.  
  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.